Treatment pathways and associated costs of metastatic colorectal cancer in Greece

Table 3 Treatment options per mutation per line (as % of patients)

	RAS mutated			BRAF mutated			RAS/BRAF WT left			RAS/BRAF WT right			MSI-H dMMR
	1st line	2nd line	3rd line	1st line	2nd line	3rd line	1st line	2nd line	3rd line	1st line	2nd line	3rd line	2nd line	3rd line
Folfiri	5	10	10	10	20				20	5				70
Folfiri & Cetuximab							15	5	10		15	10
Folfiri & Panitumumab							20	5			25	10
Folfiri & Bevacizumab	15	20		15	25		10	30		20	10
Folfiri & Aflibercept		15			10			10			10
Folfox	5	5	5	10							10
Folfox & Cetuximab					10		15	5
Folfox & Panitumumab							20	5
Folfox & Bevacizumab	35	15		5			10	28		10	10
Folfoxiri	3			20						20
Folfoxiri & Panitumumab										5
Folfoxiri & Bevacizumab	12			30						30
Capecitabine			5
Capecitabine and Oxaliplatin (CapOX)	3	10
CapOX & Bevacizumab	12	10		10
Capecitabine & Bevacizumab	10	10					10	10	10	10	10	10
Tas102			50			40			40			40
Regorafenib			30			10			10			10
Encorafenib & Cetuximab					25	50
Cetuximab									10			10
Panitumumab												10
Immunotherapies		5			10			2			10		100	30
Total	100	100	100	100	100	100	100	100	100	100	100	100	100	100

ISSN: 1478-7547